Clinical Trial of Topiramate for Cocaine Addiction

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an outpatient clinical trial of topiramate for addressing cocaine dependence and reduction of cocaine associated behaviors in opiate dependent drug users maintained on methadone treatment.

The study aims to answer whether topiramate

1. is safe and acceptable to methadone patients
2. reduces cocaine use
3. helps with collateral problems such as alcohol abuse, tobacco dependence, anxiety, PTSD and/or pain symptoms. The study will also evaluate topiramate effect on neuro-cognitive performance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1

NCT00249691

Cocaine-Related Disorders

UNKNOWN PHASE3

Topiramate to Reduce Cocaine Dependence

NCT00223626

Cocaine-Related Disorders

COMPLETED PHASE2

Topiramate for Alcohol and Cocaine Dependence

NCT00167245

Alcoholism Cocaine Dependence

COMPLETED PHASE2

Topiramate for the Treatment of Methamphetamine Dependence - 1

NCT00345371

Methamphetamine

COMPLETED PHASE2

Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence

NCT01811940

Cocaine Dependence

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an outpatient clinical trial of topiramate treatment for cocaine dependence and reduction of cocaine-associated HIV risk behavior. Topiramate is of high current interest in this regard, having been identified my National Institute on Drud Abuse (NIDA) leadership as among only a small number of tested candidates providing a "positive signal" and warranting further clinical investigation (Vocci, 2005). Topiramate is a marketed antiepileptic that enhances the GABAergic system and antagonizes the glutamatergic system, both new targets in the search for anti-cocaine treatments. A published pilot trial has supported topiramate's efficacy, and it is especially intriguing as potentially beneficial against other disorders prevalent among drug users, such as mood, anxiety, panic disorders, PTSD, pain and cognitive dysfunction, that may contribute to drug use. Design/Methods: This is phase II, double-blind randomized (stratified) 4 group, 2x2 design, evaluating topiramate versus placebo under each of two levels of cocaine-abstinence motivation -- cocaine-abstinence-contingent versus non-contingent voucher incentives. Conduct will be in a methadone maintenance context to ensure adequate retention and adherence, with participants dually dependent on opioids and cocaine. The target topiramate stabilization dose is 300 mg/day (150 mg b.i.d.), with one dose per day being observed at the clinic. The voucher-incentive manipulation provides valuable information about the role of motivation in modulating medication effects; it also provides a positive control condition to document the sensitivity of the study methods for detecting therapeutic benefit. Enrollment will be 300 patients ( 240 completers, 60/group). Participation will be up to 33 weeks - Baseline/Placebo-Run-in (5 weeks), Randomized Medication Treatment (20 weeks, induction, stable dosing, taper), Randomized Voucher Treatment (12 weeks, embedded in Medication period), and Therapeutic Disposition (up to 8 weeks). Data analysis focuses on the 8-week period of stable dosing and concurrent vouchers. The primary outcome variable is days abstinent from cocaine, as determined by a combination of self-report and objective confirmation by quantitative urinalysis toxicology of cocaine metabolite levels and application of the "Preston" rule for determining abstinence. Secondary outcome variables are measures of adverse behaviors and symptoms commonly co-occurring in cocaine abusers (alcohol abuse, tobacco use, depression, anxiety, PTSD, pain, neuro-cognitive and psychomotor performance dysfunction) that may contribute to drug use and/or detrimental effects. Significance: This randomized controlled clinical trial will provide valuable information about the actions and therapeutic effectiveness of the promising candidate anti-cocaine pharmacotherapy topiramate, and about the conditions, correlates, and modulators of any observed effectiveness. It will also provide valuable methodological information contributing to the continuing evolution of clinical trial methods for evaluating potential drug abuse treatment medications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cocaine Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 topiramate + CR

topiramate and contingency reinforcement for urine sample confirming cocaine abstinence

Group Type EXPERIMENTAL

topiramate

Intervention Type DRUG

topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.

capsules are administered from week 4 through 25 of the trial

Contingency Reinforcement

Intervention Type BEHAVIORAL

monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results

2 topiramate + NonCR

Topiramate and random reinforcement irrespective of cocaine use

Group Type EXPERIMENTAL

topiramate

Intervention Type DRUG

topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.

capsules are administered from week 4 through 25 of the trial

4 Placebo + NonCR

Group Type PLACEBO_COMPARATOR

placebo + NonCR

Intervention Type DRUG

participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence

3 Placebo + CR

Placebo and contingency reinforcement for urine sample confirming cocaine abstinence

Group Type ACTIVE_COMPARATOR

Contingency Reinforcement

Intervention Type BEHAVIORAL

monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

topiramate

topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.

capsules are administered from week 4 through 25 of the trial

Intervention Type DRUG

Contingency Reinforcement

monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results

Intervention Type BEHAVIORAL

placebo + NonCR

participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

topamax® CAS 97240-79-4 contingency management

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 - 55 years old
* active opioid and cocaine dependence
* seeking treatment for cocaine and opioid dependence
* eligible for methadone maintenance per state and federal regulations
* able and willing to provide a urine sample thrice a week
* willing to answer questionnaires on a weekly basis
* willing to provide breath samples for presence of alcohol thrice weekly
* fluent in the English language

Exclusion Criteria

* allergy to sulfonamide drugs
* diabetes, respiratory insufficiency, renal tubular acidosis, renal insufficiency, heart failure, liver insufficiency, chronic diarrhea, other chronic diseases predisposing to a risk of acidosis
* history of nephrolithiasis
* HIV positive individuals who meet AIDS criteria by CDC criteria or are taking antiretroviral medications
* serious psychiatric illness (psychosis, dementia)
* glaucoma or family history of glaucoma
* prostate hyperplasia, shy bladder, irritable bladder, difficulty providing urine samples on demand
* female participants: being pregnant, lactating, or unwilling to use an effective method of contraception
* use of antiepileptic agents
* benzodiazepine dependence
* latex allergy

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No